Research Nester released a report titled “Polycystic Ovary Syndrome Treatment Market: Global Demand Analysis & Opportunity Outlook 2027” which delivers detailed overview of the global polycystic ovary syndrome treatment market in terms of market segmentation by drugs, by surgery, by distribution channel and by region.

Further, for the in-depth analysis, the report encompasses the industry growth drivers, restraints, supply and demand risk, market attractiveness, BPS analysis and Porter’s five force model.

The market for polycystic ovary syndrome treatment is anticipated to grow by a CAGR of about 5% during the forecast period, i.e., 2019-2027. The market is segmented by drugs, by surgery, by distribution channel and by region. Out of these, the drugs segment is further segmented into oral contraceptives, insulin-sensitizing drugs, antidepressants, anti-androgen drugs and others. On the basis of these, the insulin-sensitizing drugs is estimated to hold the largest share in the polycystic ovary syndrome treatment market on account of increased demand for anti-diabetic drugs in order to decrease the insulin hormone levels, thereby controlling PCOS along with diabetes.

Geographically, the market in North America is anticipated to hold the largest share in the PCOS treatment market as a result of higher incidences of the disorder diagnosed in the region. The diagnosis of this disorder among women is anticipated to increase on account of better medical facilities and increasing awareness among women in this region. Further, the presence of leading market players in this region is another factor estimated to contribute towards the market growth.

Risks Associated with Polycystic Ovary Syndrome to Drive the Market Growth

The onset of PCOS gives rise to various other disorders related to hormonal imbalance such as diabetes and heart diseases. Moreover, the disorder affects the reproductive health of women, resulting in menstrual pain and irregular menstruation. The growing demand for prevention of PCOS and related diseases is estimated to significantly raise the growth of the market during the forecast period. However, the drugs available for the treatment of PCOS change the hormone levels in the body which lead to various side effects including body weight gain or loss, irregular menstruation, bloating and others. This is anticipated to restrict the market growth in the upcoming years.

This report also provides the existing competitive scenario of some of the key players of the global polycystic ovary syndrome treatment market which includes company profiling of Millendo Therapeutics (MLND), Inc., Bayer AG (BAYN), Ferring B.V., Novartis AG (NOVN), EffRx Pharmaceuticals SA, Bristol-Myers Squibb Company (BMY), Teva Pharmaceutical Industries Ltd. (TEVA), GlaxoSmithKline (GSK), Mylan N.V. (MYL) and Sanofi S.A. (SAN). The profiling enfolds key information of the companies which encompasses business overview, products and services, key financials and recent news and developments. On the whole, the report depicts detailed overview of the global polycystic ovary syndrome treatment market that will help industry consultants, equipment manufacturers, existing players searching for expansion opportunities, new players searching possibilities and other stakeholders to align their market centric strategies according to the ongoing and expected trends in the future.